1,733 results on '"Giamarellos-Bourboulis, Evangelos J"'
Search Results
2. Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein
3. Adjunctive treatment in COVID-19 and sepsis—What did we learn?
4. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*
5. Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control
6. Fatty acid desaturation and lipoxygenase pathways support trained immunity
7. Immune responses of patients on maintenance hemodialysis after infection by SARS-CoV-2: a prospective observational cohort study
8. Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19
9. Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity
10. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
11. An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial
12. HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL
13. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
14. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial
15. Performance evaluation of a PCR panel (FilmArray® Pneumonia Plus) for detection of respiratory bacterial pathogens in respiratory specimens: A systematic review and meta-analysis
16. A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
17. Early sepsis recognition: how difficult can this be?
18. Towards personalized medicine: a scoping review of immunotherapy in sepsis
19. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial
20. qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial
21. Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes
22. A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis
23. Dimethyl itaconate induces long-term innate immune responses and confers protection against infection
24. Correction: Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control
25. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI
26. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
27. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
28. Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial
29. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial
30. Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial etiology
31. Redefining critical illness
32. A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece
33. eLife assessment: Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia
34. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations For Developing Precision Medicine in ICU
35. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
36. Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II
37. Systematized and efficient: organization of critical care in the future
38. An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin
39. Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial
40. High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure
41. A 6-mRNA host response classifier in whole blood predicts outcomes in COVID-19 and other acute viral infections
42. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
43. Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections
44. Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
45. Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial
46. Author Correction: Transmission of trained immunity and heterologous resistance to infections across generations
47. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU.
48. Transmission of trained immunity and heterologous resistance to infections across generations
49. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
50. The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.